Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576 · see citing works

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · see citing works

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333 · see citing works

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · see citing works

The microbiome and innate immunity

Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016) · Nature · doi:10.1038/nature18847 · Cited by 2,012 · see citing works

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation

Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.-T., Grishin, N. V., et al. (2015) · Science · doi:10.1126/science.aaa2630 · Cited by 1,927 · see citing works

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

cGAS surveillance of micronuclei links genome instability to innate immunity

Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · see citing works

CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.

Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · see citing works

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works

STING is a direct innate immune sensor of cyclic di-GMP

Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570 · see citing works

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · see citing works

The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation

Zhong, B., Yang, Y., Li, S., Wang, Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien, P., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.003 · Cited by 1,513 · see citing works

Mitotic progression following DNA damage enables pattern recognition within micronuclei

Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508 · see citing works

Cancer immunotherapy: harnessing the immune system to battle cancer

Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,366 · see citing works

STING: infection, inflammation and cancer.

Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · see citing works

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works

Chromothripsis from DNA damage in micronuclei

Zhang, C., Spektor, A., Cornils, H., Francis, J. M., Jackson, E. K., Liu, S., Meyerson, M. M., & Pellman, D. S. (2015) · Nature · doi:10.1038/nature14493 · Cited by 1,153 · see citing works

Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase.

Gao, P., Ascano, M., Wu, Y., Barchet, W., Gaffney, B. L., Zillinger, T., Serganov, A. A., Liu, Y., Jones, R. A., Hartmann, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.046 · Cited by 1,101 · see citing works

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · see citing works

Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses

Gao, D., Wu, J., Wu, Y.-T., Du, F., Aroh, C., Yan, N., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1240933 · Cited by 986 · see citing works

Design of amidobenzimidazole STING receptor agonists with systemic activity

Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912 · see citing works

CAR T Cell Therapy for Solid Tumors

Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909 · see citing works

A STING-activating nanovaccine for cancer immunotherapy

Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 904 · see citing works

Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity

Schoggins, J. W., MacDuff, D. A., Imanaka, N., Gainey, M. D., Shrestha, B., Eitson, J. L., Mar, K. B., Richardson, R. B., Ratushny, A. V., Litvak, V., et al. (2014) · Nature · doi:10.1038/nature12862 · Cited by 896 · see citing works

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 802 · see citing works

Oncolytic virus therapy: A new era of cancer treatment at dawn

Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 776 · see citing works

Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1

Abe, T., & Barber, G. N. (2014) · Journal of Virology · doi:10.1128/jvi.00037-14 · Cited by 767 · see citing works

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 756 · see citing works

Activation of STING requires palmitoylation at the Golgi

Mukai, K., Konno, H., Akiba, T., Uemura, T., Waguri, S., Kobayashi, T., Barber, G. N., Arai, H., & Taguchi, T. (2016) · Nature Communications · doi:10.1038/ncomms11932 · Cited by 733 · see citing works

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720 · see citing works

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

Shae, D., Becker, K. W., Christov, P. P., Yun, D. S., Lytton‐Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M. C., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 681 · see citing works

Nuclear cGAS suppresses DNA repair and promotes tumorigenesis

Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0629-6 · Cited by 651 · see citing works

Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP

Ablasser, A., Schmid-Burgk, J. L., Hemmerling, I., Horvath, G. L., Schmidt, T., Latz, E., & Hornung, V. (2013) · Nature · doi:10.1038/nature12640 · Cited by 649 · see citing works

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 609 · see citing works

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons

Carroll, E. C., Jin, L., Mori, A., Muñoz‐Wolf, N., Oleszycka, E., Moran, H. B. T., Mansouri, S., McEntee, C. P., Lambe, E. M., Agger, E. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.004 · Cited by 599 · see citing works

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · see citing works

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589 · see citing works

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 569 · see citing works

Recognition of Endogenous Nucleic Acids by the Innate Immune System

Roers, A., Hiller, B., & Hornung, V. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.002 · Cited by 541 · see citing works

STING and the innate immune response to nucleic acids in the cytosol

Burdette, D. L., & Vance, R. E. (2013) · Nature Immunology · doi:10.1038/ni.2491 · Cited by 501 · see citing works

The host STING pathway at the interface of cancer and immunity

Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487 · see citing works

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.047 · Cited by 451 · see citing works

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 450 · see citing works

Inflammation-driven carcinogenesis is mediated through STING

Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., & Barber, G. N. (2014) · Nature Communications · doi:10.1038/ncomms6166 · Cited by 449 · see citing works

Targeting the IDO1 pathway in cancer: from bench to bedside

Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 449 · see citing works

The cGAS-STING Defense Pathway and Its Counteraction by Viruses

Ma, Z., & Damania, B. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.010 · Cited by 442 · see citing works

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

Conlon, J. E., Burdette, D. L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V. A. K., Monks, B. G., Jin, T., Xiao, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300097 · Cited by 441 · see citing works

New development in CAR-T cell therapy

Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 395 · see citing works

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 385 · see citing works

Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis

Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 384 · see citing works

Type I interferon response and innate immune sensing of cancer

Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375 · see citing works

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death

Larkin, B., Ilyukha, V., Sorokin, M., Buzdin, A., Vannier, E., & Poltorak, A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601999 · Cited by 361 · see citing works

Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System

Santaguida, S., Richardson, A., Iyer, D., M’Saad, O., Zasadil, L. M., Knouse, K. A., Wong, Y. L., Rhind, N., Desai, A. B., & Amon, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.05.022 · Cited by 355 · see citing works

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 339 · see citing works

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

Lemos, H. D. P., Mohamed, E. T., Huang, L., Ou, R., Pacholczyk, G. A., Arbab, A. S., Munn, D. H., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325 · see citing works

Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells

Tang, C.-H. A., Zundell, J. A., Ranatunga, S., Lin, C., Nefedova, Y., Valle, J. R. D., & Hu, C. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1885 · Cited by 318 · see citing works

Chimeric antigen receptor T cells: a novel therapy for solid tumors

Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306 · see citing works

Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes

Cerboni, S., Jeremiah, N., Gentili, M., Gehrmann, U., Conrad, C., Stolzenberg, M., Pïcard, C., Neven, B., Fischer, A., Amigorena, S., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161674 · Cited by 303 · see citing works

Viral apoptosis is induced by IRF‐3‐mediated activation of Bax

Chattopadhyay, S., Marques, J. T., Yamashita, M., Peters, K. L., Smith, K., Desai, A., Williams, B. R. G., & Sen, G. C. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.50 · Cited by 281 · see citing works

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

Grabosch, S., Bulatović, M., Zeng, F., Ma, T., Zhang, L., Ross, M. S., Brozick, J., Fang, Y., Tseng, G. C., Kim, E. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0581-9 · Cited by 279 · see citing works

Evolutionary Origins of cGAS-STING Signaling

Margolis, S. R., Wilson, S. C., & Vance, R. E. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.004 · Cited by 273 · see citing works

Adjuvants for cancer vaccines

Dubensky, T. W., & Reed, S. G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.007 · Cited by 259 · see citing works

Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities

Parlato, S., Santini, S. M., Lapenta, C., Pucchio, T. D., Logozzi, M., Spada, M., Giammarioli, A. M., Malorni, W., Fais, S., & Belardelli, F. (2001) · Blood · doi:10.1182/blood.v98.10.3022 · Cited by 259 · see citing works

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review

Sacher, A. G., & Gandhi, L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0639 · Cited by 255 · see citing works

STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

Ohkuri, T., Ghosh, A., Kosaka, A., Zhu, J., Ikeura, M., David, M., Watkins, S. C., Sarkar, S. N., & Okada, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0099 · Cited by 252 · see citing works

Cytosolic DNA Sensing in Organismal Tumor Control

Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250 · see citing works

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. M., & Zhao, Q. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0568-6 · Cited by 245 · see citing works

STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer

Chandra, D., Quispe‐Tintaya, W., Jahangir, A., Asafu-Adjei, D. A., Ramos, I., Sintim, H. O., Zhou, J., Hayakawa, Y., Karaolis, D. K. R., & Gravekamp, C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0123 · Cited by 234 · see citing works

Cancer immunotherapy beyond immune checkpoint inhibitors

Marin-Acevedo, J. A., Soyano, A. E., Dholaria, B., Knutson, K. L., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0552-6 · Cited by 213 · see citing works

STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells

Klarquist, J. S., Hennies, C. M., Lehn, M. A., Reboulet, R. A., Feau, S., & Janssen, E. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401869 · Cited by 211 · see citing works

Abnormal Nuclear Shape in Solid Tumors Reflects Mitotic Instability

Gisselsson, D., Björk, J., Höglund, M., Mertens, F., Cin, P. D., Åkerman, M., & Mandahl, N. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63958-2 · Cited by 210 · see citing works

Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy

Wilson, D. R., Sen, R., Sunshine, J., Pardoll, D., Green, J., & Kim, Y. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2017.10.013 · Cited by 209 · see citing works

The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells

Ho, S. S. W., Zhang, W. Y. L., Tan, N. Y. J., Khatoo, M., Suter, M. A., Tripathi, S., Cheung, F. S. G., Lim, W. K., Tan, P. H., Ngeow, J. Y. Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.010 · Cited by 206 · see citing works

Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches

Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204 · see citing works

Antigen processing and immune regulation in the response to tumours

Reeves, E., & James, E. (2016) · Immunology · doi:10.1111/imm.12675 · Cited by 199 · see citing works

Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma

Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., & Harashima, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.026 · Cited by 198 · see citing works

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 195 · see citing works

Genome-Derived Cytosolic DNA Mediates Type I Interferon-Dependent Rejection of B Cell Lymphoma Cells

Shen, Y. J., Bert, N. L., Chitre, A., Koo, C. X., Nga, X. H., Ho, S. S. W., Khatoo, M., Tan, N. Y. J., Ishii, K. J., & Gasser, S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.041 · Cited by 186 · see citing works

cGAS and Ifi204 Cooperate To Produce Type I IFNs in Response to Francisella Infection

Storek, K. M., Talmor, N., Ohlson, M. B., & Monack, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402764 · Cited by 184 · see citing works

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 181 · see citing works

RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma

Lam, A. R., Bert, N. L., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179 · see citing works

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works

Fate of micronuclei and micronucleated cells

Hintzsche, H., Hemmann, U., Poth, A., Utesch, D., Lott, J., & Stopper, H. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.002 · Cited by 168 · see citing works

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer

Kinkead, H. L., Hopkins, A. C., Lutz, E. R., Wu, A. A., Yarchoan, M. M., Cruz, K. A., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 167 · see citing works

Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

Moore, E. C., Clavijo, P. E., Davis, R. J., Cash, H. A., Waes, C. V., Kim, Y., & Allen, C. T. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0104 · Cited by 159 · see citing works

Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal

Liang, D., Huang, X., Guan-Jun, D., Hu, E., Sheng, C., Wang, T., Hu, Q., Ni, Y., & Ya-yi, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.011 · Cited by 156 · see citing works

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine

Tan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E. L., Hu, H., Chen, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2807 · Cited by 152 · see citing works

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W., & Emens, L. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0284 · Cited by 151 · see citing works

Anti–CTLA-4 therapy requires an Fc domain for efficacy

Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L. R., Garforth, S., Fedorov, E. V., Fedorov, A. A., Bonanno, J. B., Gall, C. M. L., Crowley, S. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 151 · see citing works

Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell–Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma

Jassar, A. S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M. B., Cheung, L., Burdick, M. D., Strieter, R. M., Ching, L., Kaiser, L. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1658 · Cited by 145 · see citing works

Diverse roles of STING-dependent signaling on the development of cancer

Ahn, J., Konno, H., & Barber, G. N. (2015) · Oncogene · doi:10.1038/onc.2014.457 · Cited by 142 · see citing works

Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis

de Queiroz, N. M. G. P., Xia, T., Konno, H., & Barber, G. N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0504 · Cited by 140 · see citing works

Checkpoint inhibitors in hematological malignancies

Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 136 · see citing works

The role of neoantigen in immune checkpoint blockade therapy

Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 133 · see citing works

Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis

Corbera‐Bellalta, M., Planas‐Rigol, E., Lozano, E., Terrades-García, N., Alba, M. A., Prieto‐González, S., García‐Martínez, A., Alberó, R., Enjuanes, A., Espígol‐Frigolé, G., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208371 · Cited by 125 · see citing works

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0091-4 · Cited by 100 · see citing works

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

Zhang, E., Gu, J., & Xu, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0759-3 · Cited by 99 · see citing works

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Wang, Z., & Celis, E. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1713-5 · Cited by 97 · see citing works

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice

Madhun, A. S., Haaheim, L. R., Nøstbakken, J. K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.094 · Cited by 97 · see citing works

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

McKeage, M. J., Reck, M., Jameson, M. B., Rosenthal, M. A., Gibbs, D. D., Mainwaring, P. N., Freitag, L., Sullivan, R., & von Pawel, J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.027 · Cited by 93 · see citing works

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0840-y · Cited by 91 · see citing works

Manipulation of Innate and Adaptive Immunity through Cancer Vaccines

Sayour, E. J., & Mitchell, D. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/3145742 · Cited by 63 · see citing works

New perspectives on type I IFNs in cancer

Gajewski, T. F., & Corrales, L. P. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.01.001 · Cited by 62 · see citing works

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

Пили, Р., Rosenthal, M. A., Mainwaring, P. N., van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J. W., Wong, S., & Clingan, P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3026 · Cited by 62 · see citing works

Combination and inducible adjuvants targeting nucleic acid sensors

Temizoz, B., Kuroda, E., & Ishii, K. J. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.003 · Cited by 42 · see citing works

Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1

Liu, J., Yang, Y., Wang, H., Wang, B., Zhao, K., Jiang, W., Bai, W., Liu, J., & Yin, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4833-8 · Cited by 39 · see citing works

Incorporation of functional elements enhances the antitumor capacity of CAR T cells

Qin, L., Zhao, R., & Li, P. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0088-z · Cited by 28 · see citing works

The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6

Hsu, Y.-A., Huang, C.-C., Kung, Y.-J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.047 · Cited by 26 · see citing works

Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer

Álvarez-Arguedas, S., Uranga, S., Martín, M. D. M., Elizalde, J., Gómez, A. B., Julián, E., Nardelli‐Haefliger, D., Martı́n, C., & Aguiló, N. (2018) · Translational research · doi:10.1016/j.trsl.2018.03.004 · Cited by 17 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

cGAS-STING, an important pathway in cancer immunotherapy

Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647 · see citing works

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654 · see citing works

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163 · see citing works

Targeting the tumor microenvironment in renal cell cancer biology and therapy

Heidegger, I., Pircher, A., & Pichler, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00490 · Cited by 133 · see citing works

Prospects for combining immune checkpoint blockade with PARP inhibition

Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works

Advances and perspectives of PARP inhibitors

Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117 · see citing works

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69 · see citing works

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42 · see citing works

The Innate Immune System

Heeg, K. M. (2007) · Neuroimmune biology · doi:10.1016/s1567-7443(07)00205-0

Aspects of the innate and adaptive immune responses to acute infections with BVDV

Brackenbury, L. S., Carr, B. V., & Charleston, B. (2003) · Veterinary Microbiology · doi:10.1016/j.vetmic.2003.09.004 · Cited by 58 · see citing works

Do adaptive immune cells suppress or activate innate immunity?

Zhao, J., Yang, X., Auh, S. L., Kim, K. D., Tang, H., & Fu, Y. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.10.003 · Cited by 38 · see citing works

Earthworm and innate immunity

Liu, Z., & Niu, B. (2008) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2008.04.005

Innate and adaptive immunity

Noakes, P. S., & Michaelis, L. J. (2013) · Elsevier eBooks · doi:10.1533/9780857095749.1.3 · Cited by 12 · see citing works